Swiss pharma firms Sandoz and Galenica post solid first‑half growth

Sandoz reported that its generic business recovered from a first‑quarter dip, delivering about $5.8 billion in revenue for the first six months, a 10 % increase year‑on‑year. The generics segment stabilized with a modest 1 % rise, while the biosimilar unit grew 20 % to $1.9 billion, driven by a 47 % surge in U.S. sales and a record 33 % share of total group revenue. Core EBITDA reached $1.2 billion with a margin of 20.9 %.

Galenica said its first‑semester turnover rose 7.1 % to 2.14 billion Swiss francs, accompanied by higher profit, and reaffirmed its full‑year growth targets. Both Basel‑based companies highlighted continued momentum in their pharmaceutical and health‑service operations despite broader market volatility.